Stroke ranks as the second-leading cause of death of total deaths and the third-leading cause of death and disability globally, with low- and middle-income countries bearing the highest burden of the disease [1]. Gouty Arthritis (GA) is the most common inflammatory arthritis in adults [2]. In clinical practice, the occurrence of GA has been observed to complicate the management of certain stroke patients during their hospital stay. The presence of pain exacerbates the impairment of the patient's limbs, hampers functional recovery, prolongs the hospitalization period, and contributes to the financial burden on both the patient and society. Consequently, acute stroke combined with GA warrants additional consideration. Nevertheless, there is a lack of comprehensive epidemiological data on acute stroke combined with GA.

Ischaemic stroke accounts for the highest proportion of stroke subtypes. In 2016, there were 13.7 million new incident strokes worldwide, and approximately 87 % of these were ischemic strokes [3]. In patients with ischemic stroke, antiplatelet drugs are one of the important secondary prevention measures. The efficacy of single or combination antiplatelet therapy in secondary stroke prevention has been confirmed in multiple clinical studies [4], [5], [6]. It is valuable to investigate whether various antiplatelet therapy regimens may impact the occurrence of GA in ischemic stroke patients.